SSY Group (HKG:2005) said its Baloxavir Marboxil has received registration approval from China's National Medical Products Administration as a bulk drug for marketed preparations, according to a Hong Kong bourse filing Monday.
Baloxavir Marboxil is used to treat influenza A and influenza B, the filing said.